• Saleem Ansari, Tina Mazaheri, Karen O'Donnell, Matthew Waite, Alexandra Cann, Mariana Abdel-Malek, Luke Boyle, Lucy Tweedlie, Samantha Scholtz, Saira Hameed, Chioma Izzi-Engbeaya, Harvinder Chahal, and Tricia Tan.
• Imperial Weight Centre, Imperial College Healthcare NHS Trust, London W2 1NY, United Kingdom; Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, United Kingdom.
• Clin Med (Lond). 2024 May 1; 24 (3): 100206100206.

AbstractObesity affects one in four people in the United Kingdom and costs the National Health Service (NHS) ∼£6.5 billion annually. The glucagon-like peptide-1 (GLP-1) receptor analogues, such as once-daily subcutaneous Liraglutide 3.0 mg (Saxenda®) and once-weekly subcutaneous Semaglutide 2.4 mg (Wegovy®), were approved by the National Institute of Health and Care Excellence (NICE) as a treatment for obesity and funded by the NHS for 2 years. Our local data shows that Saxenda is effective at reducing body weight and glycaemia in people with obesity and diabetes; however, the supply issues of GLP-1 receptor analogues have contributed to the unavailability of Saxenda and Wegovy in our service. Our patients are devastated that they cannot access NICE-approved GLP-1 receptor analogues for obesity. The 2-year GLP-1 receptor analogue treatment limit for obesity alongside a lack of funded NHS services and supply issues represent barriers to treatment for people living with obesity who have clear medical indications.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

19 keywords...

hide…